Please login to the form below

Not currently logged in
Email:
Password:

Lilly Leadership changes

Eli Lilly & Co has announced that Alex M Azar II is to take the top leadership role in Lilly's US B2B organisation

Eli Lilly & Co has announced that Alex M Azar II is to take the top leadership role in Lilly's US B2B organisation.

Azar, who is currently senior vice president of corporate affairs and communications will assume the role of vice president of business-to-business and Puerto Rico on April 1. In his new role, Azar will oversee Lilly's public payer, managed care and wholesaler operations in the US and oversee the company's sales and marketing operations in Puerto Rico.

Dr John C Lechleiter, chairman, president and CEO said: "Lilly has been focusing for some time on advancing our understanding of and addressing, in more meaningful ways, the needs of our public and private payer customers. Given the current and unprecedented political forces on the US healthcare system, this move will enable us to bring a more exclusive focus on these vital customers."

The company is expected to announce the appointment of a new head of global corporate affairs shortly.

Lilly has also announced that the US senior vice president of accounts-based markets, Jack Bailey, is to expand his remit to include oversight of the US diabetes business unit. Bailey is currently responsible for the company's US oncology and cardiovascular teams along with the Lilly Hospital Group.

"It was Jack's vision and leadership over the last eight years that drove the successful modernisation of Lilly's business-to-business operations in the United States," said Lechleiter. "I am pleased that he will now have the opportunity to apply his knowledge and strong track record of performance more broadly across Lilly US's therapeutic portfolio."

2nd March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics